Development of solid matrix-antibody-antigen (SMAA) complexes as multivalent subunit vaccines
MetadataShow full item record
Altmetrics Handle Statistics
In the course of the work presented in this thesis, the construction of solid matrix-antibody-antigen (SMAA) complexes as vaccines was further developed. In particular, it was demonstrated that it is feasible to assemble SMAA complexes using a short oligopeptide tag (Pk) attached to the C-termini of antigens and a Pk tag- specific mAb SV5-P-k. In order to facilitate the purification of recombinant proteins for immunization purposes, a second affinity tag was attached to the antigen N-termini. Initially, the N-terminal tag was 26-kDa-large thrombin-removable glutathione S-transferase (GST), which permitted first-step purification on immobilized glutathione. However, because of problems with protein insolubility and the proteolytical removal of GST from the hybrid proteins, the GST domain was substituted by an N-terminal 12-amino acid-long tag (His) containing an array of 6 histidines. The His tag was small and thus did not require removal prior to immunization, and allowed purification of His-linked proteins on a nickel-affinity column. Moreover, it was possible to preform nickel-affinity chromatography under protein denaturing conditions, which allowed purification of insoluble or aggregated proteins. In addition, novel prokaryotic expression vectors were constructed for a single-cloning-step addition of these N- and C-terminal tags to proteins of interest. These vectors were used to individually express all non-glycosylated products encoded by the simian immunodeficiency virus (SIV) in E. coli. The SIV envelope glycoprotein gp160 with the Pk tag attached to its C-terminus was expressed in insect cells and first-step purified on a lentile lectin column. Following the first purification step on either nickel or lentile columns, all SIV proteins were purified and successfully incorporated into SMAA complexes using anti-Pk tag mAb SV5-P-k. Thus, efficient purification protocols were developed, which purified recombinant proteins via two different affinity tags attached to their N- and C-termini and isolated predominantly full-size proteins. As a stage in achieving the goal of human multivalent vaccines, the SV5-P-k mAb was humanized and is currently being expressed in Chinese hamster ovary cells.
Thesis, PhD Doctor of Philosophy
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.